This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Phase 1
Active, not recruiting
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Drug: KGX101- Cohort 3Drug: KGX101- Cohort -1Drug: KGX101- Cohort 2Drug: KGX101- Cohort 5Drug: KGX101- Cohort 4Drug: KGX101- Cohort 1
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Kangabio AUSTRALIA LTD PTY
- Target Recruit Count
- 54
- Registration Number
- NCT06074497
- Locations
- 🇦🇺
Pindara Private Hospital, Benowa, Queensland, Australia
🇦🇺Sunshine Coast University Private Hospital, Birtinya, Queensland, Australia
🇦🇺Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath